Short interest for Immunovant gives investors a sense of the degree to which investors are betting on the decline of Immunovant's stock. Short interest data is updated every two weeks.

Immunovant Stock (NASDAQ:IMVT), Short Interest Report

Immunovant

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACON

AHCO

ANNX

ATAK

BYTS

CALT

CLNN

CPRX

CYTK

DUNE

FDMT

GENE

GMBL

GSAT

HOOK

ICCT

IMVT

IREN

ISPR

LGVN

MDVL

MGTX

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

NOGN

PBLA

PETV

PRZO

RCAC

SAVA

SFWL

SUPV

SXTP

UUUU

ZJYL

Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings.

Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Biotech

Large Cap

Health Care

General

ROIV

Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in 

Autoimmune Disease Player Immunovant&#39;s Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%

Price Target

Pre-Market Outlook

Analyst Ratings

AMZN

ARGX

CRWD

GKOS

PODD

SPOT

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday

Immunovant Inc

WIIM

STGW

Stagwell shares are trading higher after the company reported better-than-expected Q1 financial results.

<p>JMP Securities  analyst Nicholas Jones   reiterates Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Market Outperform and maintains $225 price target.</p>


Reiteration

JMP Securities Reiterates Market Outperform on Amazon.com, Maintains $225 Price Target

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>American Intl Gr</strong>.</p>
<p>Looking at options history for American Intl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) we detected 13 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish expectations and 46% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $255,981 and 10, calls, for a total amount of $662,389.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $70.0 and $82.0 for American Intl Gr, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for American Intl Gr options trades today is 2339.9 with a total volume of 3,258.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for American Intl Gr's big money trades within a strike price range of $70.0 to $82.0 over the last 30 days.</p>
<h3>American Intl Gr Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714577527_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AIG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$1.75</td>
<td>$1.7</td>
<td>$1.7</td>
<td>$72.50</td>
<td>$155.9K</td>
<td>1.2K</td>
<td>10</td>
</tr>
<tr>
<td>AIG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$2.55</td>
<td>$2.5</td>
<td>$2.5</td>
<td>$77.50</td>
<td>$140.7K</td>
<td>8.6K</td>
<td>1.0K</td>
</tr>
<tr>
<td>AIG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$4.0</td>
<td>$3.9</td>
<td>$4.0</td>
<td>$75.00</td>
<td>$140.0K</td>
<td>6.8K</td>
<td>16</td>
</tr>
<tr>
<td>AIG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$2.75</td>
<td>$2.7</td>
<td>$2.7</td>
<td>$77.50</td>
<td>$118.0K</td>
<td>8.6K</td>
<td>447</td>
</tr>
<tr>
<td>AIG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$15.8</td>
<td>$15.4</td>
<td>$15.6</td>
<td>$70.00</td>
<td>$57.7K</td>
<td>234</td>
<td>37</td>
</tr>
</tbody>
</table>
</p>
<h3>About American Intl Gr</h3>
<p>American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. The company recently spun off its life insurance operations (Corebridge), but still retains a majority stake.</p>
<h3>American Intl Gr's Current Market Status</h3>
<ul>
<li>With a volume of 919,092, the price of AIG is up 0.74% at $75.87. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 0 days.</li>
</ul>
<h3>Expert Opinions on American Intl Gr</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $82.4.</p>
<ul>
<li>An analyst from JP Morgan has decided to maintain their Neutral rating on American Intl Gr, which currently sits at a price target of $80. </li>
<li>Consistent in their evaluation, an analyst from Keefe, Bruyette &amp; Woods keeps a Outperform rating on American Intl Gr with a target price of $86. </li>
<li>Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on American Intl Gr with a target price of $87. </li>
<li>An analyst from Evercore ISI Group persists with their In-Line rating on American Intl Gr, maintaining a target price of $80. </li>
<li>An analyst from Morgan Stanley persists with their Equal-Weight rating on American Intl Gr, maintaining a target price of $79. </li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest American Intl Gr options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

American Intl Gr's Options: A Look at What the Big Money is Thinking

<p>Deep-pocketed investors have adopted a bearish approach towards Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ENPH usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Enphase Energy. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 22% leaning bullish and 66% bearish. Among these notable options, 4 are puts, totaling $120,053, and 5 are calls, amounting to $246,981.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $107.0 to $200.0 for Enphase Energy over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Enphase Energy stands at 551.44, with a total volume reaching 467.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Enphase Energy, situated within the strike price corridor from $107.0 to $200.0, throughout the last 30 days.</p>
<h3>Enphase Energy Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714577521_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ENPH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$4.85</td>
<td>$4.8</td>
<td>$4.83</td>
<td>$120.00</td>
<td>$86.5K</td>
<td>3.3K</td>
<td style="text-align: right;">196</td>
</tr>
<tr>
<td>ENPH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$13.5</td>
<td>$13.45</td>
<td>$13.45</td>
<td>$110.00</td>
<td>$53.8K</td>
<td>179</td>
<td style="text-align: right;">47</td>
</tr>
<tr>
<td>ENPH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/24/24</td>
<td>$4.75</td>
<td>$4.65</td>
<td>$4.65</td>
<td>$113.00</td>
<td>$39.0K</td>
<td>26</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>ENPH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/10/24</td>
<td>$3.85</td>
<td>$3.75</td>
<td>$3.75</td>
<td>$108.00</td>
<td>$38.2K</td>
<td>45</td>
<td style="text-align: right;">109</td>
</tr>
<tr>
<td>ENPH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$91.25</td>
<td>$89.25</td>
<td>$91.25</td>
<td>$200.00</td>
<td>$36.5K</td>
<td>0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Enphase Energy</h3>
<p>Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.</p>
<p>After a thorough review of the options trading surrounding Enphase Energy, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Enphase Energy</h3>
<ul>
<li>With a volume of 787,998, the price of ENPH is down -1.81% at $106.79. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 85 days.</li>
</ul>
<h3>Professional Analyst Ratings for Enphase Energy</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $129.2.</p>
<ul>
<li>In a cautious move, an analyst from Roth MKM downgraded its rating to Buy, setting a price target of $140. </li>
<li>An analyst from B. Riley Securities has decided to maintain their Buy rating on Enphase Energy, which currently sits at a price target of $133. </li>
<li>Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Enphase Energy, targeting a price of $130. </li>
<li>Maintaining their stance, an analyst from BMO Capital continues to hold a Market Perform rating for Enphase Energy, targeting a price of $113. </li>
<li>An analyst from RBC Capital has decided to maintain their Outperform rating on Enphase Energy, which currently sits at a price target of $130. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Enphase Energy, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


ENPH

This Is What Whales Are Betting On Enphase Energy

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Cleveland-Cliffs</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CLF, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Cleveland-Cliffs.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 40% bullish and 60%, bearish.</p>
<p>Out of all of the special options we uncovered, 7 are puts, for a total amount of $406,901, and 3 are calls, for a total amount of $165,991.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $16.0 to $26.5 for Cleveland-Cliffs over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Cleveland-Cliffs's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Cleveland-Cliffs's whale activity within a strike price range from $16.0 to $26.5 in the last 30 days. </p>
<h3>Cleveland-Cliffs Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714577515_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CLF</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.85</td>
<td>$5.75</td>
<td>$5.85</td>
<td>$22.00</td>
<td>$138.6K</td>
<td>743</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>CLF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.4</td>
<td>$2.33</td>
<td>$2.39</td>
<td>$17.00</td>
<td>$94.6K</td>
<td>3.3K</td>
<td style="text-align: right;">683</td>
</tr>
<tr>
<td>CLF</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$5.25</td>
<td>$5.15</td>
<td>$5.25</td>
<td>$22.00</td>
<td>$85.0K</td>
<td>218</td>
<td style="text-align: right;">177</td>
</tr>
<tr>
<td>CLF</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.55</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$20.00</td>
<td>$70.7K</td>
<td>250</td>
<td style="text-align: right;">273</td>
</tr>
<tr>
<td>CLF</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.44</td>
<td>$2.41</td>
<td>$2.41</td>
<td>$17.00</td>
<td>$42.6K</td>
<td>3.3K</td>
<td style="text-align: right;">86</td>
</tr>
</tbody>
</table>
</p>
<h3>About Cleveland-Cliffs</h3>
<p>Cleveland-Cliffs Inc is a flat-rolled steel producer and manufacturer of iron ore pellets in North America. It is organized into four operating segments based on differentiated products, Steelmaking, Tubular, Tooling and Stamping and European Operations, but operates through one reportable segment -Steelmaking. It is vertically integrated from mined raw materials, direct reduced iron, and ferrous scrap to primary steelmaking and downstream finishing, stamping, tooling and tubing. It serves a diverse range of other markets due to its comprehensive offering of flat-rolled steel products. Geographically, it operates in the United States, Canada and other countries. The majority of revenue is from the United States. It is a supplier of steel to the automotive industry in North America.</p>
<p>Following our analysis of the options activities associated with Cleveland-Cliffs, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Cleveland-Cliffs Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 4,773,900, with CLF's price down by -1.48%, positioned at $16.65.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 82 days.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cleveland-Cliffs options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Unpacking the Latest Options Trading Trends in Cleveland-Cliffs

<p>Benchmark  analyst Kurt Hallead   reiterates Tetra Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTI#NYSE">TTI</a>) with a Buy and maintains $8 price target.</p>


Benchmark Reiterates Buy on Tetra Technologies, Maintains $8 Price Target

<p>Applied Industrial Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) has outperformed the market over the past 5 years by 13.85% on an annualized basis producing an average annual return of 25.55%. Currently, Applied Industrial Techs has a market capitalization of $7.07 billion. </p>
<p><strong>Buying $1000 In AIT:</strong> If an investor had bought $1000 of AIT stock 5 years ago, it would be worth <strong>$3,029.55</strong> today based on a price of $183.25 for AIT at the time of writing.</p>
<h3>Applied Industrial Techs's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714577423_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In Applied Industrial Techs 5 Years Ago Would Be Worth This Much Today

<p>Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) has outperformed the market over the past 20 years by 6.11% on an annualized basis producing an average annual return of 14.04%. Currently, Martin Marietta Materials has a market capitalization of $35.86 billion. </p>
<p><strong>Buying $100 In MLM:</strong> If an investor had bought $100 of MLM stock 20 years ago, it would be worth <strong>$1,384.54</strong> today based on a price of $581.09 for MLM at the time of writing.</p>
<h3>Martin Marietta Materials's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714577418_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $100 Invested In Martin Marietta Materials 20 Years Ago Would Be Worth Today

<p>JP Morgan  analyst Brian Ossenbeck   maintains Werner Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WERN#NASDAQ">WERN</a>) with a Neutral and lowers the price target from $37 to $36.</p>


WERN

JP Morgan Maintains Neutral on Werner Enterprises, Lowers Price Target to $36

TSLA

Tesla Retreats From Next-generation 'Gigacasting' Manufacturing Process, Sources Say

<p>Benchmark  analyst Todd Brooks   reiterates Denny's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DENN#NASDAQ">DENN</a>) with a Buy and maintains $15 price target.</p>


DENN

Benchmark Reiterates Buy on Denny's, Maintains $15 Price Target

<p>JP Morgan  analyst Peter Peng   maintains Skyworks Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) with a Neutral and lowers the price target from $120 to $105.</p>


SWKS

JP Morgan Maintains Neutral on Skyworks Solutions, Lowers Price Target to $105

<p>The <strong>SPDR S&amp;P 500</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spy#NYSE">SPY</a>) was falling about 0.25% lower Wednesday ahead of the <strong>Federal Reserve&rsquo;s</strong> <strong>decision on interest rates</strong>.</p>
<p>The central bank is widely expected to hold rates steady but investors will be focusing on Fed chair <strong>Jerome Powell&rsquo;s</strong> comments at the press conference following the decision for clues as to when the Fed may begin easing.</p>
<p>After the SPY ran about 27% higher between Oct. 27 and March 28, the ETF entered into a downtrend, retracing about 4.6% from the all-time high of $524.61. Whether or not downward pressure across major equities will continue through to the end of the second quarter remains to be seen but for at least the short term, from a technical analysis perspective, the market ETF is showing weakness, trading mostly sideways on lower-than-average volume.</p>
<p><em>Read Next:&nbsp;<a href="https://www.benzinga.com/general/biotech/24/04/38535093/april-showers-on-wall-street-miners-utilities-emerge-as-bright-spots-in-gloomy-market">April Showers On Wall Street: Miners, Utilities Emerge As Bright Spots In Gloomy Market</a></em></p>
<p><em>Trending:&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/05/38549891/cannabis-advocates-say-deas-move-represents-progress-but-not-justice-ends-war-on-medical-marijua">Cannabis Advocates Say DEA&#39;s Move Represents &#39;Progress But Not Justice,&#39; Ends War On Medical Marijuana Patients, But Not War On Drugs</a></em></p>
<p>More experienced traders who wish to play the SPY either bullishly or bearishly may choose to do so through <a href="https://www.direxion.com/product/daily-sp-500-bull-bear-3x-etfs">one of two Direxion ETFs</a>. Bullish traders can enter a short-term position in <strong>Direxion Daily S&amp;P 500 Bull 3X Shares</strong> (ARCA: SPXL) and bearish traders can trade the inverse ETF, <strong>Direxion Daily S&amp;P 500 Bear 3X Shares</strong> (ARCA: SPXS).</p>
<p>The ETFs: SPXL and SPXS are triple leveraged funds that track the movement of the SPY, seeking a return of 300% or &ndash;300% on the return of the benchmark index over a single day.</p>
<p>It should be noted that leveraged ETFs are meant to be used as a trading vehicle as opposed to long-term investments</p>
<p><em>Want direct analysis? Find me in the BZ Pro lounge! <a href="http://www.benzinga.com/pro">Click here for a free trial</a>.</em></p>
<p><strong>The SPY Chart:</strong> After closing at the $495.16 level on April 19, the SPY has been trading mostly sideways near the $500 mark, within a slight uptrend pattern. The most recent higher high within the pattern was formed on Monday at $510.75 and the most recent confirmed lower low was printed at $497.49 on April 25.</p>
<ul>
<li>On Tuesday, the SPY dropped 1.29% from its opening price and on Wednesday, the ETF was trading slightly lower on very low volume and working to print a small doji candlestick, which could indicate the next local low has occurred and a bounce will take place on Thursday.</li>
<li>For the uptrend to continue on the daily chart, the SPY will eventually need to close above the most recent higher high. If that fails to happen, the uptrend will be negated and another downtrend could be on the horizon.</li>
<li>If the SPY forms another higher high, the ETF will regain the 50-day simple moving average (SMA) as support, which would give bullish traders more confidence. If the SPY retraces significantly, it&rsquo;s likely to find support, at least temporarily, at the 200-day SMA.</li>
<li>The SPY has resistance above at $502.87 and at $510.13 and support below at $496.05 and at $491.42.<img alt="screenshot_592.png" src="https://www.benzinga.com/files/u278075/screenshot_592.png" style="height:354px; width:760px" /></li>
</ul>
<p><em>Image sourced from Shutterstock</em></p>


Long Ideas

Sector ETFs

Short Ideas

Technicals

ETFs

SPXL

SPXS

The Stock Market Slips Ahead Of Fed's Policy Meeting As Investors Brace For Persistently High Rates

<p>Benchmark  analyst Daniel Kurnos   reiterates Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) with a Buy and maintains $15 price target.</p>


SEAT

Benchmark Reiterates Buy on Vivid Seats, Maintains $15 Price Target

<p>JP Morgan  analyst Anupam Rama   maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Overweight and lowers the price target from $29 to $28.</p>


SAGE

JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $28

<p>Benchmark  analyst Bill Sutherland   reiterates Huron Consulting Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURN#NASDAQ">HURN</a>) with a Buy and maintains $140 price target.</p>


HURN

Benchmark Reiterates Buy on Huron Consulting Gr, Maintains $140 Price Target

<p>JP Morgan  analyst Tami Zakaria   maintains PACCAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) with a Overweight and lowers the price target from $140 to $130.</p>


PCAR

JP Morgan Maintains Overweight on PACCAR, Lowers Price Target to $130

<p><strong>Alibaba Group Holding Limited</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) plans to construct a data center in Vietnam to meet legal requirements for local data storage and to cater to increasing demand in one of Asia&#8217;s fastest-growing economies. </p>
<p>Currently, Alibaba rents server space from Vietnamese state-owned telecommunications companies Viettel and VNPT. </p>
<p>The arrangement follows Vietnam&#8217;s contentious 2022 law mandating that companies store data within the country—a regulation that sparked resistance from major tech firms like&nbsp;<strong>Alphabet Inc</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)&nbsp;<strong>Google&nbsp;</strong>and&nbsp;<strong>Amazon.Com Inc&nbsp;</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), the Nikkei Asia&nbsp;<a target="_blank" href="https://asia.nikkei.com/Business/Technology/Alibaba-to-build-Vietnam-data-center-to-follow-local-storage-law" rel="noreferrer noopener">reports</a>.</p>
<p>Dang Minh Tam, Alibaba Cloud&#8217;s solution architect lead, noted that the company uses colocation services from these state companies to store client data locally. It also maintains backups across its server farms in regions including Taiwan and Singapore.&nbsp;</p>
<p>The move is part of Alibaba&#8217;s strategy to ensure better security and control over its data and potentially reduce costs and liability issues associated with multi-company data management.&nbsp;</p>
<p>Companies including&nbsp;<strong>Nvidia Corp&nbsp;</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>),&nbsp;<strong>Apple Inc&nbsp;</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), and&nbsp;<strong>Lam Research Corp</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) have reached out to Vietnam to diversify their supply chain base amid heightening geopolitical tensions between the US and China.</p>
<p>Lam Research&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/03/37886908/lam-research-eyes-vietnam-to-diversify-supply-chain-away-from-china-report" rel="noreferrer noopener">weighed the supply chain shift</a>&nbsp;to Vietnam, with the Vietnamese government canvassing the former to commit $1 billion to local production efforts.</p>
<p>&nbsp;Apple&nbsp;<a target="_blank" href="https://www.benzinga.com/government/24/04/38460042/apple-strengthens-supply-chain-in-china-while-growing-presence-in-southeast-asia-and-india" rel="noreferrer noopener">suppliers in Vietnam</a>&nbsp;increased by 40% to 35 in 2023.</p>
<p>Meanwhile, Nvidia tapped&nbsp;<a target="_blank" href="https://www.benzinga.com/government/23/12/36171360/whats-going-on-with-nvidia-stock-monday" rel="noreferrer noopener">Vietnamese tech firms</a>&nbsp;for AI development.</p>
<p>Alibaba stock lost over 11% in the last 12 months. Investors can gain exposure to the stock via&nbsp;<strong>Invesco Golden Dragon China ETF</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGJ#NASDAQ">PGJ</a>) and&nbsp;<strong>Tidal Trust II CoreValues Alpha Greater China Growth ETF</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGRO#NYSE">CGRO</a>).</p>
<p><strong>Price Action: </strong>BABA shares are trading higher by 1.28% at $75.78 at the last check on Wednesday.</p>
<p><strong><em>Disclaimer:</em></strong><em> This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors</em></p>
<p><em>Alibaba Photo by zhu difeng on Shutterstock</em></p>


Government

Regulations

Tech

Media

AAPL

BABA

CGRO

GOOG

GOOGL

LRCX

NVDA

PowerShares Golden Dragon Halter USX China Portfolio

After Nvidia and Apple, Alibaba Chases Vietnam: New Data Center to Boost Control and Meet Local Laws

<p>JP Morgan  analyst Steven Alexopoulos   maintains MVB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVBF#NASDAQ">MVBF</a>) with a Overweight and lowers the price target from $28 to $25.</p>


MVBF

JP Morgan Maintains Overweight on MVB Financial, Lowers Price Target to $25

Management

Tesla's Top HR Executive Allie Arebalo Has Left The Company

Wells Fargo screens for momentum names to play and contrarian plays to avoid

Corinne Johnson, an analyst from Goldman Sachs, has initiated a new Buy rating on Immunovant (IMVT). Corinne Johnson's rating is based on the promi...

Immunovant Inc.: A Strong Buy on IMVT-1402's Market Potential and Upcoming Clinical Catalysts

Immunovant Inc (IMVT) is up 2.15% today. IMVT has an Overall Score of 49. Find out what this means to you and get the rest of the rankings on IMVT!See Full IMVT ReportIMVT stock closed at $31.57 and is up $0.68 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investo

Premarket Mover: Immunovant Inc (IMVT) Up 2.15%

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Immunovant (IMVT – Research Report), with a price target of...

Buy Rating for Immunovant Amidst Strong Market Position and Promising Batoclimab Trials

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Some of the market&rsquo;s favorite <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> have created immense wealth, as in the recent weight-loss drug stock boom.&nbsp;</p>



<p>On May 26,&nbsp;<strong>Viking Therapeutics</strong>&nbsp;(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/vktx-stock-quote/"><strong>VKTX</strong></a></span>) was trading&nbsp;<a href="https://investorplace.com/2023/05/3-biotech-stocks-sitting-on-huge-upside-catalysts/">around $20.25</a>. Today, after hitting a high of $99.41, it trades at $69.55 &ndash; again &ndash; an impressive opportunity. Or, look at&nbsp;<strong>Eli Lilly</strong>&nbsp;(NYSE:<span><a href="https://investorplace.com/stock-quotes/lly-stock-quote/"><strong>LLY</strong></a></span>).&nbsp;<a href="https://investorplace.com/2023/05/3-biotech-stocks-sitting-on-huge-upside-catalysts/">In May 2022</a>, it traded near $375. Now, after hitting a high of $784, it&rsquo;s at $770.</p>



<p>That, plus&nbsp;innovation, demand for better treatment, pharmaceutical companies strengthening pipelines, and a resurgence of M&amp;A,&nbsp;biotech stocks&nbsp;could offer some of the most explosive opportunities.</p>



<p>Also,&nbsp;according to Market.us, the global biotech market that was valued at $1.023 trillion in 2022 could be worth over <a href="https://finance.yahoo.com/news/biotechnology-market-anticipates-soaring-staggering-123200858.html">$3.67 trillion by 2032</a>.</p>



<p>With plenty of catalysts ahead, let&rsquo;s examine three more of the market&rsquo;s favorite biotech stocks to buy and hold today.</p>



<h2><strong>Terns Pharmaceuticals (TERN)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/pharmaceutical1600-300x169.png" alt="pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory"><div>Source: Dmitry Kalinovsky / Shutterstock.com</div></div><p>Investors may want to keep an eye on&nbsp;<strong>Terns Pharmaceuticals</strong>&nbsp;(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tern-stock-quote/"><strong>TERN</strong></a></span>). While it already ran from a low of $3.50 to $6.60, it offers plenty of future upside potential.</p>



<p>The clinical-stage biopharmaceutical company owns a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity.&nbsp;It expects to post data from its <a href="https://seekingalpha.com/news/4079774-terns-to-report-phase-1-data-on-glp-1-drug-in-2h-2024">Phase 1 study</a>&nbsp;for its oral GLP-1 obesity drug TERN-601 in the second half of the year.&nbsp;As we near that data, expect TERN to run even more. </p>



<p>Further, the company has $263.3 million in cash on hand. That&rsquo;s sufficient to support its expenses through 2026.&nbsp;</p>



<p>Outside of obesity, the&nbsp;U.S. Food and Drug Administration (<strong>FDA</strong>) just granted orphan <a href="https://www.onclive.com/view/tern-701-receives-fda-orphan-drug-designation-in-cml">drug designation</a> for its TERN-701&nbsp;treatment of&nbsp;chronic myeloid leukemia. This treatment is currently in Phase 1 clinical development with interim data expected in the second half of the year.&nbsp;</p>



<h2><strong>Immunovant (IMVT)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/11/shutterstock_1667119063-300x169.png" alt="Pipette adding fluid to one of several test tubes; biotech NVTA Stock"><div>Source: motorolka / Shutterstock.com</div></div><p>Another one of the Street&rsquo;s favorite biotech stocks is&nbsp;<strong>Immunovant&nbsp;</strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/imvt-stock-quote/"><strong>IMVT</strong></a></span>), where recent weakness is an opportunity.</p>



<p>First, analysts see promise in the company&rsquo;s lead drug candidate, batoclimab, for issues such as thyroid eye disease and myasthenia gravis. Next, the company just noted that a &ldquo;Phase 3 trial of&nbsp;batoclimab showed that the monoclonal antibody led to sustained improvement for patients with&nbsp;generalized myasthenia gravis&nbsp;(<strong>gMG</strong>), as compared with placebo,&rdquo;&nbsp;<a href="https://www.ajmc.com/view/batoclimab-outperforms-placebo-in-phase-3-generalized-mg-trial">according to AJMC.com</a>.</p>



<p>Also,&nbsp;LifeSci analysts are maintaining <a href="https://markets.businessinsider.com/news/stocks/buy-rating-for-immunovant-amidst-strong-market-position-and-promising-batoclimab-trials-1033186547#:~:text=In%20a%20report%20released%20today,for%20treating%20autoantibody%2Dmediated%20diseases.">a buy rating</a> on IMVT and a $53 price target. Goldman Sachs initiated coverage with a buy rating with a $50 target.</p>



<p>&ldquo;Goldman Sachs has projected peak sales for IMVT-1402 [a potential treatment of IgG-mediated autoimmune diseases] to reach $4.4 billion, assuming the drug&rsquo;s efficacy aligns with that of the most advanced competitors. However, the firm also suggests there could be an upside potential of up to $6.2 billion in peak sales if IMVT-1402 proves to be best-in-class in terms of efficacy,&rdquo; <a href="https://www.investing.com/news/stock-market-news/goldman-sachs-sets-50-target-on-immunovant-shares-sees-upside-93CH-3336526">noted by Investing.com</a>.</p>



<p>Even George <a href="https://finance.yahoo.com/news/10-stocks-george-soros-insiders-110444100.html">Soros is a fan</a> of the stock, holding a $6 million stake in IMVT. Steven Cohen&rsquo;s Point72 also just bought 2.67 million shares of IMVT, as noted by Hedge Follow.</p>



<h2><strong>ProShares Ultra NASDAQ Biotechnology ETF (BIB)</strong></h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/05/etf-blocks-1600-300x169.jpg" alt='the word "etf" spelled out in many yellow cubes against a background of many black cubes'><div>Source: shutterstock.com/Imagentle</div></div><p>Or, if you&rsquo;d prefer to gain exposure to 225 biotech stocks at a low cost, examine&nbsp;<strong>the ProShares Ultra NASDAQ Biotechnology ETF</strong>&nbsp;(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/bib-stock-quote/"><strong>BIB</strong></a></span>).&nbsp;</p>



<p>With an <a href="https://www.proshares.com/our-etfs/leveraged-and-inverse/bib">expense ratio of 0.95%</a>,&nbsp;the fund seeks daily investment results of two times the daily performance of the&nbsp;Nasdaq Biotechnology Index. Since November, the ETF ran from a low of $41.74 to a recent high of $62. Now at $57.81, I&rsquo;d like to see the BIB ETF closer to $70 near-term and $100 over the long haul.</p>



<p>Some of BIB&rsquo;s top holdings include&nbsp;<strong>Amgen</strong>&nbsp;(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/amgn-stock-quote/"><strong>AMGN</strong></a></span>),&nbsp;<strong>Biogen</strong>&nbsp;(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/biib-stock-quote/"><strong>BIIB</strong></a></span>),&nbsp;<strong>Gilead Sciences</strong>&nbsp;(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/gild-stock-quote/"><strong>GILD</strong></a></span>) and&nbsp;<strong>Vertex Pharmaceuticals</strong>&nbsp;(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/vrtx-stock-quote/"><strong>VRTX</strong></a></span>).</p>



<p>What&rsquo;s nice about an ETF like the BIB is that we can gain exposure to a good deal of solid biotech stocks. All will be impacted by the catalysts mentioned earlier. And instead of paying $27,600 for 100 shares of Amgen, for example, we can pay $5,600 for 100 shares of an ETF that exposes us to AMGN. It&rsquo;s cheaper and safer.</p>



<p><em>On the date of publication, Ian Cooper did not hold (either directly or indirectly) any positions in the securities mentioned. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.</em></p>
<div><p>Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/03/wall-streets-favorite-biotech-stocks-3-names-that-could-make-you-filthy-rich/">Wall Street&#8217;s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Wall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

Analyst Derek Archila from Wells Fargo maintained a Buy rating on Immunovant (IMVT – Research Report) and keeping the price target at $48.00. Derek...

Buy Rating Affirmed for Immunovant on Strong Drug Development Prospects and Efficacy Confidence

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 4/22/2024, According to Top Analysts

Baron Health Care Fund Q1 2024 Shareholder Letter

In a report released today, Yasmeen Rahimi from Piper Sandler initiated coverage with a Buy rating on Immunovant (IMVT – Research Report) and a pri...

Immunovant (IMVT) Gets a Buy from Piper Sandler

ACLX

AMGN

ASND

AZNCF

BHVN

BIIB

BPMC

CHRW

CYBR

DELL

DOCU

ESTC

ETSY

EXAS

EXPD

FOXA

GILD

GPCR

GRND

ICLR

INFA

IRTC

ISRG

LEGN

MTUM

NEOG

NTRA

RCKT

RGEN

ROKU

SGRY

SWAV

TERN

TOST

TROW

UBER

VKTX

VRTX

XENE

Earnings

Press Releases

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

Immunovant to Present at Upcoming Investor Conferences

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Immunovant Stock (NASDAQ:IMVT), Short Interest Report

People Also Watch